Herzog, Chiara http://orcid.org/0000-0002-1572-498X
Sundström, Karin
Jones, Allison
Evans, Iona
Barrett, James E.
Wang, Jiangrong
Redl, Elisa
Schreiberhuber, Lena
Costas, Laura
Paytubi, Sonia
Dostalek, Lukas
Zikan, Michal
Cibula, David
Sroczynski, Gaby
Siebert, Uwe
Dillner, Joakim
Widschwendter, Martin http://orcid.org/0000-0002-7778-8380
Funding for this research was provided by:
Secretariat for Universities and Research of the Department of Business and Knowledge of the Generalitat de Catalunya project (2017SGR01085)
Horizon 2020 Framework Programme (634570, 634570, 634570, 634570)
The Eve Appeal
European Research Council (742432)
Article History
Received: 6 April 2022
Accepted: 10 October 2022
First Online: 21 November 2022
Declarations
:
: Ethical approval was granted by local ethics committees for all sample collections, and written informed consent to participate was obtained from each participant where applicable. Briefly, liquid-based cytology samples processed in the capital region of Stockholm in Sweden are biobanked through a state-of-the-art platform at the Karolinska University Laboratory, Karolinska University Hospital. Collection of samples is based on an opt-out system, with samples biobanked by default unless opted out. Ethical approval for use of samples and linked disease status information in the current study was granted by the Karolinska Ethical Committee (Dnr 2014/1242-31/4).
: Not applicable.
: J.E.B., A.J., I.E., and M.W. are named as inventors on a patent (submitted by UCLB, UCL’s technology transfer organisation) which partly covers aspects described in this paper. C.H., J.E.B., and M.W. are shareholders in Sola Diagnostics GmbH, which holds an exclusive licence to the intellectual property that protects the commercialisation of the WID™-qCIN test. L.C. received supplies from Integrated DNA Technologies—IDT—and Roche Diagnostics at 50% discount for a pilot study (includes 13 self-samples of this study) and has received speakers’ honoraria from Roche.